Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gossamer Bio, Inc. - Common Stock (NQ:GOSS)

0.1672 +0.0016 (+0.97%)
Streaming Delayed Price Updated: 10:11 AM EDT, Jun 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gossamer Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Gossamer Bio, Inc. (GOSS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Gossamer Bio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – GOSS
From DJS LAW GROUP
Via Business Wire
News headline image
Securities Fraud Investigation Into Gossamer Bio, Inc. (GOSS) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
GOSS Investors Have Opportunity to Lead Gossamer Bio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (NASDAQ:GOSS) and Encourages Investors with Large Losses to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Investor Notice: Robbins LLP Informs Investors of the Gossamer Bio, Inc. Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
GOSS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Gossamer Bio (GOSS) Investors of Securities Class Action Deadline on June 1, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
From Pomerantz LLP
Via GlobeNewswire
News headline image
GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
These stocks are the most active in today's session ↗
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Check out the stocks that are attracting the most attention and driving market activity. ↗
Via Chartmill
News headline image
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? ↗
Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial. 
Via Stocktwits
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Participate in Upcoming Investor Conferences
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio to Participate in Upcoming Investor Conferences
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
From Gossamer Bio, Inc.
Via Business Wire
News headline image
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
From Gossamer Bio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.